Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EncisionECIA 35 Buyback Yield % is 0.00 as of Aug. 29, 2026. GuruFocus rates ECIA with a GF Score™ of 35/100 and a GF Value™ of $0.34 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 325 Medical Devices & Instruments companies, Encision ranks worse than 307692% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Encision's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ECIA vs GCTK, YBGJ, RSCF: Buyback Yield % Comparison
For the Medical Instruments & Supplies subindustry, Encision's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Encision Buyback Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Encision's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Encision's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Encision (ECIA) has a Buyback Yield % of 0.00 as of Aug. 29, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Encision and its competitors. According to the industry distribution chart, Encision ranks #999999 out of 325 companies in the Medical Devices & Instruments industry.
Is Encision's Buyback Yield % too high?
Encision's current Buyback Yield % is 0.00. Based on the distribution chart, Encision ranks #999999 out of 325 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Encision has a GF Score™ of 35/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Encision's Buyback Yield % compare to GCTK and YBGJ?
According to the Medical Devices & Instruments industry distribution chart, Encision ranks #999999 out of 325 companies for Buyback Yield %. This places Encision in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Devices & Instruments company?
A good Buyback Yield % depends on the Medical Devices & Instruments industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Encision and its competitors. Encision's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Encision stock overvalued right now?
Based on GuruFocus' analysis, Encision (ECIA) is currently considered Possible Value Trap. The stock's GF Value™ is $0.34, compared to a current price of $0.19 — trading 44.1% below its estimated fair value. The current Buyback Yield % is 0.00. Encision's overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Encision (ECIA), the current Buyback Yield % is 0.00 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Encision (ECIA) Overvalued in 2026?
Based on GuruFocus' analysis, Encision stock appears to be undervalued.
The current stock price of $0.19 is trading 44.1% below its estimated GF Value™ of $0.34.
GuruFocus considers Encision to be Possible Value Trap.
Key valuation signals for ECIA:
Buyback Yield %: 0.00
GF Value™: $0.34 vs. price of $0.19 (44.1% below fair value)
No single metric tells the full story. See the ECIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Encision Inc is a medical device company. The company develops and markets technology that provides unprecedented outcomes and patient safety in minimally invasive surgery. The company has established and developed AEM (Active Electrode Monitoring) technology and surgical instruments which provide surgeons with the desired tissue effects of cutting and coagulating tissue in laparoscopic procedures while preventing stray electrosurgical energy that can cause complications and even death. The segments of the company are Product and Service. Product designs develops, manufactures and markets patented surgical instruments. Service performs electrical engineering activities for external entities. Maximum revenue is generated from the product segment.
35GF Score
Get the complete analysis for ECIA
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ECIA has been successfully added to your 
